Elsevier

The Lancet

Volume 345, Issue 8952, 25 March 1995, Pages 745-748
The Lancet

COMMENTARY
Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients

https://doi.org/10.1016/S0140-6736(95)90637-1Get rights and content

Abstract

For patients with gastric cancer deemed curable the only treatment option is surgery, but there is disagreement about whether accompanying lymph-node dissection should be limited to the perigastric nodes (D1) or should extend to regional lymph nodes outside the perigastric area (D2). We carried out a multicentre randomised comparison of D1 and D2 dissection. 1078 patients were randomised (539 to each group). 26 allocated D1 and 56 allocated D2 were found not to satisfy eligibility criteria (histologically confirmed adenocarcinoma of the stomach without clinical evidence of distant metastasis). Each of the remainder was attended by one of eleven supervising surgeons who decided whether curative resection was possible and, if so, assisted with the allocated procedure. Among the 711 patients (380 D1, 331 D2) judged to have curable lesions, D2 patients had a higher operative mortality rate than D1 patients (10 vs 4%, p=0·004) and experienced more complications (43 vs 25%, p<0·001). They also needed longer postoperative hospital stays (median 25 [range 7-277] vs 18 [7-143] days, p<0·001). Morbidity and mortality differences persisted in almost all subgroup analyses. While we await survival results, D2 dissection should not be used as standard treatment for western patients.

References (16)

  • Jj Bonenkamp et al.

    A comparison of factors influencing the prognosis of Japanese and Western gastric cancer patients

    World J Surg

    (1993)
  • K. Maruyama et al.

    Progress in gastric cancer surgery and its limits of radicality

    Word J Surg

    (1987)
  • Mt Diggory et al.

    R2/3 gastrectomy for gastric carcinoma: an audited experience of a consecutive series

    Br J Surg

    (1985)
  • Dm Dent et al.

    Randomised comparison of R1 and R2 gastrectomy for gastric carcinoma

    Br J Surg

    (1988)
  • Hj Wanebo et al.

    Cancer of the stomach: a patient care study by the American College of Surgeons

    Ann Surg

    (1993)
  • Mf Shiu et al.

    Adenocarcinoma of the stomach: a multivariate analysis of the clinical, pathological and treatment factors

    Hepato-Gastroenterol

    (1989)
  • Jd Roder et al.

    Prognostic factors in gastric carcinoma: results of the German Gastric Carcinoma Study 1992

    Cancer

    (1993)
There are more references available in the full text version of this article.

Cited by (991)

  • Advances in Gastric Cancer Surgical Management

    2024, Hematology/Oncology Clinics of North America
  • PDT for Gastric Cancer — the view from China

    2023, Photodiagnosis and Photodynamic Therapy
View all citing articles on Scopus
View full text